Locations
San Diego, CA, USA · Kalamazoo, MI, USA · Liberty Station, San Diego, CA, USA
Size
11 - 50 employees
Stage
Other
founded in
2015
Cirius Therapeutics is a clinical-stage company that develops insulin sensitizers for the treatment of non-alcoholic steatohepatitis. The company is developing MSDC-0602K, a next-generation insulin sensitizer for the treatment of nonalcoholic steatohepatitis (NASH). MSDC-0602K is currently being evaluated in a Phase 2b clinical trial. Through its novel insulin-sensitizing mechanism of action, MSDC-0602K has the potential to resolve the underlying pathophysiology of NASH. Cirius Therapeutics focuses on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases. It was founded in 2015 and is based in Kalamazoo, Michigan, United States.
Something looks off?